“调神理气”针刺法治疗轻度抑郁症的临床和机制研究

注册号:

Registration number:

ITMCTR2200006378

最近更新日期:

Date of Last Refreshed on:

2022-07-25

注册时间:

Date of Registration:

2022-07-25

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

“调神理气”针刺法治疗轻度抑郁症的临床和机制研究

Public title:

Study on the clinical and mechanism of ''Tiaoshen liqi'' acupuncture in the treatment of mild depression

注册题目简写:

English Acronym:

研究课题的正式科学名称:

“调神理气”针刺法治疗轻度抑郁症的临床和机制研究

Scientific title:

Study on the clinical and mechanism of ''Tiaoshen liqi'' acupuncture in the treatment of mild depression

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200062150 ; ChiMCTR2200006378

申请注册联系人:

白露

研究负责人:

邹伟

Applicant:

Lu Bai

Study leader:

Wei Zou

申请注册联系人电话:

Applicant telephone:

15945978008

研究负责人电话:

Study leader's telephone:

13351980999

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

blkeyan@163.com

研究负责人电子邮件:

Study leader's E-mail:

kuangzou1965@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

黑龙江省哈尔滨市香坊区和平路26号黑龙江中医药大学附属第一医院

研究负责人通讯地址:

黑龙江省哈尔滨市香坊区和平路26号黑龙江中医药大学附属第一医院

Applicant address:

The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, 26 Heping Road, Xiangfang District, Harbin, Heilongjiang, China

Study leader's address:

The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, 26 Heping Road, Xiangfang District, Harbin, Heilongjiang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

黑龙江中医药大学

Applicant's institution:

Heilongjiang University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

HZYLLKY202205001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

黑龙江中医药大学附属第一医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Heilongjiang University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

1990/1/1 0:00:00

伦理委员会联系人:

赵楠

Contact Name of the ethic committee:

Nan Zhao

伦理委员会联系地址:

黑龙江省哈尔滨市香坊区和平路26号

Contact Address of the ethic committee:

26 Heping Road, Xiangfang District, Harbin, Heilongjiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

黑龙江中医药大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

研究实施负责(组长)单位地址:

黑龙江省哈尔滨市香坊区和平路26号黑龙江中医药大学附属第一医院

Primary sponsor's address:

The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, 26 Heping Road, Xiangfang District, Harbin, Heilongjiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

黑龙江省

市(区县):

哈尔滨

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

黑龙江中医药大学附属第一医院

具体地址:

黑龙江省哈尔滨市香坊区和平路26号

Institution
hospital:

The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

Address:

26 Heping Road, Xiangfang District, Harbin, Heilongjiang, China

经费或物资来源:

自筹经费及科室赞助

Source(s) of funding:

Self-financing and section sponsorship

研究疾病:

轻度抑郁症

研究疾病代码:

Target disease:

mild depression

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

横断面

Cross-sectional

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.评价针灸治疗轻度抑郁症的疗效和安全性; 2.观察轻度抑郁症患者氧化应激相关指标的变化,探讨针灸治疗抑郁症的可能机制。

Objectives of Study:

1.Evaluate the efficacy and safety of the treatment of mild depression by acupuncture treatment; 2.Observe the changes of oxidative stress related indexes in mild depressed patients and to explore the possible mechanisms of acupuncture in the treatment for depression.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合《国际疾病分类(第 10版)》(ICD-10)轻度抑郁症的诊断标准; 2.年龄 18到 70岁之间; 3.HDRS-24:20≤评分≤26分; 4.近 1月内未曾参加过其它临床试验的患者; 5.近 1周内未接受针对抑郁症的针灸及药物等治疗的患者; 6.没有失语和智力障碍,能理解量表内容并配合 4周的针灸治疗并签署知情同意书的患者。

Inclusion criteria

1. Meet the diagnostic criteria for mild depression of the International Classification of Diseases 10th revision (ICD-10). 2. Aged between 18 and 70 years. 3. The score of HDRS-24: 20 ≤HDRS≤ 26. 4. Patients who have not participated in other clinical trials within the last 1 month. 5. Patients who have not received treatment such as acupuncture and medication for depression within the last 1 week. 6. Patients who do not have aphasia or mental retardation, can understand the content of the scale and cooperate with 4 weeks of acupuncture treatment and follow-up for 3 months and sign an informed consent form.

排除标准:

1.符合精神分裂症、双相抑郁症或其他精神性障碍诊断标准,有自杀倾向的患者; 2.伴有严重心、肝、肾等系统疾病患者; 3.孕妇或哺乳期妇女; 4.不能耐受针刺,或针刺部位皮肤有感染、破溃,凝血功能障碍、易于晕针、极度虚弱的患者; 5.本研究开始前 1个月内曾参加过其它临床试验的患者; 6.本研究开始前 1周内曾服用抗抑郁药物或己接受针对抑郁证的针灸治疗的患者; 7.伴有严重认知及意识障碍等影响交流沟通、不愿配合的患者,并且未签署知情同意书。

Exclusion criteria:

1. Meet the diagnostic criteria for schizophrenia, bipolar depression or other psychotic disorders with suicidal tendencies. 2. Patients with severe heart, liver, kidney and other systemic diseases. 3. Pregnant or lactating women. 4. Patients who cannot tolerate needling, or who have skin infection or breakdown at the site of needling, coagulation disorders, easy to get dizzy, or extreme weakness. 5. Patients who have participated in other clinical trials within 1 month prior to the start of this study. 6. Patients who have taken antidepressants or received acupuncture treatment for depression within 1 week prior to the start of this study. 7. Patients with severe cognitive and consciousness impairment that affects communication and unwillingness to cooperate, and who have not signed the informed consent form.

研究实施时间:

Study execute time:

From 2022-06-23

To      2023-06-23

征募观察对象时间:

Recruiting time:

From 2022-07-25

To      2023-02-23

干预措施:

Interventions:

组别:

试验组

样本量:

35

Group:

Experimental group

Sample size:

干预措施:

调神理气针刺

干预措施代码:

Intervention:

“Tiaoshen liqi”acupuncture

Intervention code:

组别:

对照组

样本量:

35

Group:

Control group

Sample size:

干预措施:

传统针刺

干预措施代码:

Intervention:

Conventional acupuncture

Intervention code:

样本总量 Total sample size : 70

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

黑龙江省

市(区县):

哈尔滨市

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

黑龙江中医药大学附属第一医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

不良反应量表

指标类型:

副作用指标

Outcome:

TESS

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者健康问卷9项

指标类型:

次要指标

Outcome:

PHQ-9

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氧化应激指标

指标类型:

附加指标

Outcome:

oxidative stress markers

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿抑郁量表

指标类型:

主要指标

Outcome:

HDRS-24

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

哥伦比亚自杀量表

指标类型:

副作用指标

Outcome:

C-SSRS

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

世界卫生组织生存质量测定简表

指标类型:

次要指标

Outcome:

WHOQOL-BREF

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究人员使用SAS9.4统计软件使用随机区组设计生成随机数,使用4和6随机块大小的1:1分配按中心分层。

Randomization Procedure (please state who generates the random number sequence and by what method):

Researchers used SAS 9.4 statistical software to generate random numbers using a randomized block design, stratified by center using a 1:1 allocation of random block sizes of 4 and 6.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结果将在学位论文上发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The results of the research will be published in the dissertation

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统